BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

974 related articles for article (PubMed ID: 26197969)

  • 1. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
    Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS.
    Ke YD; van Hummel A; Stevens CH; Gladbach A; Ippati S; Bi M; Lee WS; Krüger S; van der Hoven J; Volkerling A; Bongers A; Halliday G; Haass NK; Kiernan M; Delerue F; Ittner LM
    Acta Neuropathol; 2015 Nov; 130(5):661-78. PubMed ID: 26437864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.
    Igaz LM; Kwong LK; Lee EB; Chen-Plotkin A; Swanson E; Unger T; Malunda J; Xu Y; Winton MJ; Trojanowski JQ; Lee VM
    J Clin Invest; 2011 Feb; 121(2):726-38. PubMed ID: 21206091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43.
    Xu YF; Prudencio M; Hubbard JM; Tong J; Whitelaw EC; Jansen-West K; Stetler C; Cao X; Song J; Zhang YJ
    PLoS One; 2013; 8(7):e69864. PubMed ID: 23922830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withania somnifera Reverses Transactive Response DNA Binding Protein 43 Proteinopathy in a Mouse Model of Amyotrophic Lateral Sclerosis/Frontotemporal Lobar Degeneration.
    Dutta K; Patel P; Rahimian R; Phaneuf D; Julien JP
    Neurotherapeutics; 2017 Apr; 14(2):447-462. PubMed ID: 27928708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-43 Proteinopathy.
    Spiller KJ; Cheung CJ; Restrepo CR; Kwong LK; Stieber AM; Trojanowski JQ; Lee VM
    J Neurosci; 2016 Jul; 36(29):7707-17. PubMed ID: 27445147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death.
    Xiao S; Sanelli T; Chiang H; Sun Y; Chakrabartty A; Keith J; Rogaeva E; Zinman L; Robertson J
    Acta Neuropathol; 2015 Jul; 130(1):49-61. PubMed ID: 25788357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy.
    Turner BJ; Bäumer D; Parkinson NJ; Scaber J; Ansorge O; Talbot K
    BMC Neurosci; 2008 Oct; 9():104. PubMed ID: 18957104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice.
    Xu YF; Zhang YJ; Lin WL; Cao X; Stetler C; Dickson DW; Lewis J; Petrucelli L
    Mol Neurodegener; 2011 Oct; 6():73. PubMed ID: 22029574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
    Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
    JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U.
    Tsai KJ; Yang CH; Fang YH; Cho KH; Chien WL; Wang WT; Wu TW; Lin CP; Fu WM; Shen CK
    J Exp Med; 2010 Aug; 207(8):1661-73. PubMed ID: 20660618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS.
    Mitchell JC; Constable R; So E; Vance C; Scotter E; Glover L; Hortobagyi T; Arnold ES; Ling SC; McAlonis M; Da Cruz S; Polymenidou M; Tessarolo L; Cleveland DW; Shaw CE
    Acta Neuropathol Commun; 2015 Jun; 3():36. PubMed ID: 26108367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.
    Wegorzewska I; Bell S; Cairns NJ; Miller TM; Baloh RH
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18809-14. PubMed ID: 19833869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders.
    Hortobágyi T; Troakes C; Nishimura AL; Vance C; van Swieten JC; Seelaar H; King A; Al-Sarraj S; Rogelj B; Shaw CE
    Acta Neuropathol; 2011 Apr; 121(4):519-27. PubMed ID: 21360076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration.
    Gomez-Deza J; Lee YB; Troakes C; Nolan M; Al-Sarraj S; Gallo JM; Shaw CE
    Acta Neuropathol Commun; 2015 Jun; 3():38. PubMed ID: 26108573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.
    Wils H; Kleinberger G; Janssens J; Pereson S; Joris G; Cuijt I; Smits V; Ceuterick-de Groote C; Van Broeckhoven C; Kumar-Singh S
    Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3858-63. PubMed ID: 20133711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms.
    Scherz B; Rabl R; Flunkert S; Rohler S; Neddens J; Taub N; Temmel M; Panzenboeck U; Niederkofler V; Zimmermann R; Hutter-Paier B
    PLoS One; 2018; 13(5):e0197674. PubMed ID: 29787578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice.
    Walker AK; Tripathy K; Restrepo CR; Ge G; Xu Y; Kwong LK; Trojanowski JQ; Lee VM
    Hum Mol Genet; 2015 Dec; 24(25):7241-54. PubMed ID: 26476406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.
    Zhao B; Cowan CM; Coutts JA; Christy DD; Saraph A; Hsueh SCC; Plotkin SS; Mackenzie IR; Kaplan JM; Cashman NR
    Acta Neuropathol Commun; 2023 Dec; 11(1):200. PubMed ID: 38111057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.